Churchill Capital Corp X (NASDAQ:CCCX) shares are trading higher Thursday after Infleqtion announced a partnership with ...
Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...
Arvinas has announced positive biomarker, pharmacokinetic and pharmacodynamic data from two Phase I studies assessing ARV-102 ...
The SHARON trial is ongoing and will be expanding to include patients without a BRCA or PALB2 mutation, and General Oncology plans to continue evaluating outcomes and long-term follow-up in this ...
A team from the Faculty of Physics and the Center for Quantum Optical Technologies at the University of Warsaw has developed ...
Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaRecommendation based on LUNA 3 phase 3 study ...
ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102 ...
NMIMS to roll out AI-led interviews with sentiment tracking, measuring facial expressions, tone, and confidence of MBA ...
The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback